New drug IBI3033 tested for safety in healthy people
NCT ID NCT07311226
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing the safety and how the body handles a single dose of IBI3033 in 32 healthy Chinese adults. Participants receive either the drug or a placebo and are monitored for side effects and drug levels over 12 weeks. Since it involves healthy people, there is no direct treatment benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI3033
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, 200080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates